Previous Close | 0.4550 |
Open | 0.4660 |
Bid | 0.4582 x 800 |
Ask | 0.4697 x 800 |
Day's Range | 0.4500 - 0.4769 |
52 Week Range | 0.2900 - 0.8400 |
Volume | |
Avg. Volume | 124,087 |
Market Cap | 22.194M |
Beta (5Y Monthly) | -0.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4100 |
Earnings Date | Nov 13, 2023 - Nov 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for AIM
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023. In addition to the presentation, the Company is proud to announce its sponsorship of the event. Details for the presentation are a
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC) Planned Phase 2 study in early-stage TNBC to determine if CKM including Ampligen may be a safe and effective alternative to pembrolizumab or in addition to pembrolizumab/NAC Results now available on ClinicalTrials.gov OCALA, Fla., Sept. 11, 2023 (GLOBE NEWS
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registere